Cancer and the Celtic Curse: How iron overload raises cancer risk in people with genetic hemochromatosis
 |
| Photo courtesy of National Cancer Institute US |
Even more unfortunate, there is a genetic condition that can cause this iron overload, even when you're eating a well-balanced diet. It's called Hereditary Hemochromatosis (HH), and it is particularly prevalent in people whose genetic background is Celtic, meaning Irish, Scottish, and to a lesser extent English and white northern European.
When you look up information about hereditary hemochromatosis, the summary on standard public health portals like NHS England, usually sounds relatively manageable: a genetic condition where the body absorbs too much iron, leading to fatigue, joint pain, and if left untreated, damage to parts of the body such as the liver, pancreas and heart; however, iron levels can be returned to normal by giving blood.
Dig a little deeper and you find that "liver damage" can include liver cancer. But mainstream coverage of HH often fails to reflect the mounting genetic research that shows untreated iron overload creates a fertile environment for cancer cells to thrive throughout the body. Understanding this, knowing how easily it can be prevented, is a powerful reason to find out if you carry the genes for HH.
Iron as cancer fuel
While iron is vital for carrying oxygen in our blood, it is volatile when present in excessive amounts. When your body lacks the genetic "brakes" to regulate iron absorption, most commonly due to two copies of a gene mutation called C282Y, excess iron spills out of normal storage proteins into your organs and bloodstream. This extra, unmanaged iron triggers two cellular disasters:
- Cellular Damage (Free Radicals): the free-floating iron reacts with oxygen to generate destructive molecules called free radicals. These molecules strip electrons from surrounding tissue, damaging cellular DNA and introducing mutations that can trigger cancer.
- Feeding Tumor Growth: cancer cells have an aggressive appetite for iron, using it to fuel rapid cell division and building new DNA. Basically, excess tissue iron acts like high-octane fuel for early-stage tumor growth.
Cancer risk from iron overload: the numbers
Translating complex genetic studies into clear, real-world numbers helps illustrate why early detection of iron overload and hereditary hemochromatosis is critical.
1. Liver Cancer: A 10-Fold Increase for Men
The most striking impact of untreated HH is on the liver, where the body stores the vast majority of excess iron.
- The risk: men with two copies of the primary HH gene mutation (C282Y homozygotes) are 10 times more likely to develop primary liver cancer compared to the general population.
- In simple terms: roughly 1 in 14 men with untreated HH will develop liver cancer by age 75 (compared to less than 1 in 150 men without the mutation).
- The unseen risk: while liver cancer often follows cirrhosis (severe liver scarring), large studies show that 10% to 15% of HH patients who develop liver cancer have no cirrhosis at all. The excess iron directly damages DNA long before total organ failure occurs.
2. Prostate Cancer
While mainstream health sites rarely mention non-liver or extrahepatic cancers, large population studies such as the 450,000-person UK Biobank study have uncovered significant links.
- The risk: men carrying two copies of the C282Y mutation show a 32% increased risk of developing prostate cancer.
- In simple terms: about 1 in 7 men with high-risk HH genes are projected to develop prostate cancer by age 75, compared to about 1 in 10 in the broader population. Because iron accumulates in glandular tissues, the prostate appears particularly vulnerable to chronic oxidative stress.
3. Colorectal and breast Cancers: The Broader Debate
Earlier, smaller studies suggested that individuals with HH had double or triple the risk for bowel (colorectal) and breast cancers. However, recently developed large-scale genetic databases indicate that the overall population risk increase for these specific cancers may be smaller than once feared. Despite this, the underlying biological mechanism remains: excess tissue iron promotes inflammation and tumor proliferation.
Gender and HH risk factors
You may have noticed that men feature heavily in HH cancer statistics. This isn't because women are genetically immune, but because of biological protection. Throughout their younger lives, women lose iron naturally through menstruation and pregnancy. This slows down iron accumulation.
However, after menopause, a woman’s iron levels begin to climb. While women with HH develop liver cancer at significantly lower rates than men, post-menopausal women with undiagnosed HH can still experience dangerous systemic iron buildup if left unchecked.
I have written about the menopausal aspects of the hemochromatosis "gender gap" on the Hemopause website. In fact, I created the term hemopause to encapsulate the increased risk that women face due to medical ignorance and male bias in medicine. The all-too-common tendency of doctors to ascribe all symptoms reported by women at or around menopause to "the change" can delay the diagnosis of iron overload triggered by hemochromatosis and the end of menstruation.
(In my opinion, hemopause is just more one example of how medicine has failed, harmed, dismissed, and demoralized women for centuries. A human tragedy that is far from being corrected.)
The bright side: simple and effective prevention
Here is the most crucial fact that every public campaign should highlight: iron overload cancer risks are almost entirely preventable if caught early. Simply put: because the risk is driven by stored iron, removing that excess iron neutralizes the hazard.
- The Treatment: The primary treatment for HH is simple therapeutic phlebotomy or venesection, removing blood at regular intervals, through exactly the same process as a standard blood donation.
- The Result: if iron levels are brought down to normal ranges before severe liver damage or cirrhosis occurs, a person’s overall cancer risk drops significantly, approaching that of the general population.
- The Win-Win: in many health systems, blood drawn during routine maintenance phlebotomy can be donated to save other lives.
Taking control: know your status
Hereditary hemochromatosis is one of the most common genetic conditions in people of Northern European ancestry—affecting roughly 1 in 150 to 1 in 200 people—yet millions remain undiagnosed. Because early symptoms like joint pain or mild fatigue are easy to dismiss, many people do not discover they have HH until organ damage has already begun.
A simple blood test checking your Serum Ferritin and Transferrin Saturation, followed by a routine genetic cheek swab or blood test, can tell you if you are at risk.
If you have a family history of unexplained liver issues, early arthritis, or heart problems, or if you simply want to take charge of your long-term health, ask your doctor about checking your iron levels. If you get pushback, question it and/or go to a different doctor, and/or buy the tests yourself.
If you have any Celtic ancestry at all, throw that into the doctor-patient conversation. The Celtic connection to hemochromatosis is the one fact that nearly every doctor has heard of (if yours has not, show him this article). Take heart from knowing that finding out early can turn a potentially life-threatening cancer risk into a easily manageable condition.
Notes
I, Stephen Cobb, wrote this article with research assistance from Gemini AI and background information from, among others: IronDisorders; HaemochromatosisUK; The High-Maintenance Body In Practice; CelticCurse; CobbsBlog; Hemopause; She'sNotOkay; and Facebook.
Comments
Post a Comment